Table 2.

Recruiting and not-yet-recruiting trials for FAP-specific PET on clinicaltrials.gov.

Title	Estimated Enrollment	Estimated Study Completion Date	Tumors	Tracer	Location	Key Interventions
The Role of 68Ga-FAPI-04 PET/CT in Gastric and Pancreatic Cancers	25 patients	06/2021	Pancreatic Cancer Gastric Cancer	68Ga-FAPI-04	Tel-Aviv Sourasky Medical Center	Head-to-head comparison between FAP-specific PET and FDG PET (max. interval: 10 days) Immunohistochemical staining of FAP in removed tumors for correlation with imaging
68Ga-FAPI PET Imaging in Malignancy	30 patients	12/2021	Various	68Ga-FAPI (not specified)	Stanford University Hospitals and Clinics	FAP-specific PET will be assessed for feasibility on a Likert scale from 1 (non-diagnostic) to 5 (excellent)
Comparison of FDG and FAPI in Patients With Various Types of Cancer	600 patients	12/2021	Various	68Ga-FAPI-04	The First Affiliated Hospital of Xiamen University	Head-to-head comparison between FAP-specific PET and FDG PET
PET Biodistribution Study of 68Ga-FAPI-46 in Patients With Prostate Cancer: A Prospective Exploratory Biodistribution Study With Histopathology Validation	30 patients	07/2023	Prostate Cancer	68Ga-FAPI-46	UCLA/Jonsson Comprehensive Cancer Center	Assessment of biodistribution Immunohistochemical staining of FAP in removed tumors for correlation with imaging Comparison between FAP-specific PET and previously performed PSMA PET (max. interval: 3 months)
PET Biodistribution Study of 68Ga-PSMA-11 and 68Ga-FAPI-46 in Patients With Non-Prostate Cancers: An Exploratory Biodistribution Study With Histopathology Validation	30 patients	10/2021	Various	68Ga-FAPI-46	UCLA/Jonsson Comprehensive Cancer Center	Assessment of biodistribution Immunohistochemical staining of FAP in removed tumors for correlation with imaging Optional head-to-head comparison with PSMA PET
PET Biodistribution Study of 68Ga-FAPI-46 in Patients With Different Malignancies: An Exploratory Biodistribution Study With Histopathology Validation	30 patients	07/2024	Various	68Ga-FAPI-46	UCLA/Jonsson Comprehensive Cancer Center	Assessment of biodistribution Immunohistochemical staining of FAP in removed tumors for correlation with imaging Comparison between FAP-specific PET and previously performed FDG/DOTATE/FDOPA or other PET (max. interval: 3 months)
Positron Nuclide Labeled NOTA-FAPI PET Study in Lymphoma	200 patients	12/2020	Lymphoma	68Ga-FAPI-0418F-FAPI-04	Peking University Cancer Hospital	Head-to-head comparison between FAP-specific PET and FDG PET (max. interval: 10 days)
PET Biodistribution Study of 68Ga-FAPI-46 in Patients With Sarcoma: An Exploratory Biodistribution Study With Histopathology Validation	30 patients	07/2024	Sarcoma	68Ga-FAPI-46	UCLA/Jonsson Comprehensive Cancer Center	Assessment of biodistribution Immunohistochemical staining of FAP in removed tumors for correlation with imaging Comparison between FAP-specific PET and previously performed FDG PET (max. interval: 3 months)